CSJA.F CSL LTD SPON.ADR 2

Healthcare Biotechnology Frankfurt Exchange
30.40 EUR
Close of Nov 11, 2026
12.53 31.00
Market cap
EUR 58.4B
P/E
-
P/B
4.37x
ROE
-17.4%
Dividend yield
2.02%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CSJA.F undervalued?

Graham number

The Graham number of CSL LTD SPON.ADR 2 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CSL LTD SPON.ADR 2 fundamental analysis

No fundamental analysis for CSL LTD SPON.ADR 2 yet.

CSL LTD SPON.ADR 2 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CSL LTD SPON.ADR 2

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, mar…

Full company profile